Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lucitanib - Advenchen Laboratories/Shanghai Institute of Materia Medica

X
Drug Profile

Lucitanib - Advenchen Laboratories/Shanghai Institute of Materia Medica

Alternative Names: AL 3810; CO-3810; E-3810 - Ethical Oncology Science; S-80881; S-80881-2

Latest Information Update: 15 Jul 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Advenchen Laboratories; Shanghai Institute of Materia Medica
  • Developer Bristol-Myers Squibb; Clovis Oncology; HaiHe Biopharma; Servier; Shanghai Institute of Materia Medica
  • Class Acetamides; Antineoplastics; Cyclopropanes; Naphthalenes; Phenyl ethers; Quinolines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Fibroblast growth factor receptor antagonists; Platelet derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c-kit inhibitors; Proto oncogene proteins c raf inhibitors; Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Small cell lung cancer
  • Phase II Gynaecological cancer; Malignant thymoma; Nasopharyngeal cancer; Solid tumours
  • Discontinued Breast cancer; Non-small cell lung cancer

Most Recent Events

  • 03 Jun 2022 Efficacy and safety data from phase II trial in LIO-1 trial in Gynaecological cancer presented at 58th Annual Meeting of the American Society of Clinical Oncology (ASCO-2022)
  • 24 Apr 2022 Phase-II clinical trials in Malignant thymoma in China (unspecified route) (Haihe Biopharma pipeline, April 2022)
  • 24 Apr 2022 Phase-II clinical trials in Nasopharyngeal cancer (Combination therapy) in China (unspecified route) (Haihe Biopharma pipeline, April 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top